Log In
BCIQ
Print this Print this
 

VSV-EBOV (V920)

Also known as: rVSV-EBOV, rVSV-ZEBOV-GP, VSV-ZEBOV (BPSC1001)

  Manage Alerts
Collapse Summary General Information
Company NewLink Genetics Corp.
DescriptionRecombinant vesicular stomatitis virus (rVSV) vaccine expressing an Ebola virus protein
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase III
Standard IndicationEbola
Indication DetailsPrevent Ebola virus infection; Treat Ebola virus infection
Regulatory Designation U.S. - Breakthrough Therapy (Prevent Ebola virus infection);
EU - PRIority MEdicines (PRIME) (Prevent Ebola virus infection)
PartnerMerck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$50.0M

$30.0M

$20.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/24/2014

$50.0M

$30.0M

$20.0M

Get a free BioCentury trial today